Skip to main content
. 2022 Dec 30;43(6):1140–1149. doi: 10.19852/j.cnki.jtcm.20221230.001

Figure 3. Effect of Naoluoxintong and its split prescriptions on the VEGFA, VEGFR2 and CD31 protein expression within frontoparietal cortex in the experimental rats (immunofluorescence staining, × 400, n = 6).

Figure 3

A/B/C: representative images of a histological section of VEGFA/ VEGFR2/CD31; A1, A2, and A3 are VEGFA/VEGFR2, DAPI, and Merge, respectively, in the sham group (saline, 14 d); B1, B2 and B3 were VEGFA/VEGFR2/CD31, DAPI, and Merge, respectively, in the model group (saline, 14 d); C1, C2 and C3 were VEGFA/VEGFR2/CD31, DAPI, and Merge, respectively, in the Nimodiping group (8.1 mg/kg, 14 d); D1, D2 and D3 were VEGFA/VEGFR2/CD31, DAPI, and Merge, respectively, in the Naoluoxintong group (7.2 g/kg, 14 d); E1, E2 and E3 were VEGFA/VEGFR2/CD31, DAPI, and Merge, respectively, in the Yiqi group (2.7 g/kg, 14 d). F1, F2 and F3 VEGFA/VEGFR2, DAPI, and Merge, respectively, in the Huoxuetongluo group (4.5 mg/kg, 14 d). VEGFA: vascular endothelial growth factor A; VEGFR2: vascular endothelial growth factor receptor 2; CD31: platelet endothelial cell adhesion molecule-1.